Natera executive chairman sells shares for $261,449

AUSTIN, TX—Natera, Inc. (NASDAQ:NTRA), a company whose stock has surged over 60% in the past year according to InvestingPro data, saw its Executive Chairman Matthew Rabinowitz recently sell a portion of his holdings. On April 28, Rabinowitz sold 1,718 shares of Natera’s common stock at an average price of $152.18 per share, amounting to a total transaction value of $261,449. Following this sale, Rabinowitz holds 2,362,570 shares directly in the $20.5 billion market cap company.

The transaction was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs), as disclosed in a footnote accompanying the filing. Additionally, Rabinowitz’s spouse holds 84,000 shares indirectly, which remain unchanged following the transaction. With Natera maintaining a strong financial health score and robust liquidity position (current ratio of 4.0), investors following the stock may be interested in the company’s upcoming earnings report on May 7. InvestingPro subscribers can access detailed analysis and 10+ additional key insights about Natera’s financial outlook.

In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, surpassing Wall Street expectations with a revenue of $476 million, a 53% increase year-over-year, and a narrower-than-expected loss per share of -$0.41. Analysts from TD Cowen and Canaccord Genuity have both maintained a Buy rating for Natera, with price targets set at $195, citing strong sales projections and robust growth levers. Canaccord Genuity highlighted the company’s success in achieving positive operating cash flows for four consecutive quarters and noted expectations for continued revenue growth in 2025. Additionally, Natera announced the U.S. launch of its Signatera Genome assay, a test designed to detect circulating tumor DNA for cancer management, supported by a large-scale clinical study. The company also initiated the HEROES clinical trial in France, aiming to explore therapy de-escalation in metastatic HER2+ breast cancer patients using the Signatera test. As Natera expands its product offerings and clinical trials, the company continues to receive positive feedback from the medical community, as seen in the recent updates to the NCCN guidelines, which now include Signatera for certain cancer types.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.